- Home
- GXAI vs MYNZ Comparison
GXAI vs MYNZ Comparison
Compare GXAI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | MYNZ |
|---|---|---|
| Founded | 2021 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 8.8M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GXAI | MYNZ |
|---|---|---|
| Price | $1.17 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 171.2K | ★ 275.1K |
| Earning Date | 11-13-2025 | 12-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $694,278.00 | $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23205.74 | N/A |
| 52 Week Low | $1.00 | $0.92 |
| 52 Week High | $3.36 | $8.20 |
Technical Indicators
Market Signals| Indicator | GXAI | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 62.12 |
| Support Level | $1.02 | $1.08 |
| Resistance Level | $1.25 | $1.35 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 73.91 | 76.00 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.